Clinical experience with an ovarian stimulation protocol for intrauterine insemination adopting a gonadotropin releasing hormone antagonist at low dose

References

• European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001;16:644–51
   PubMed Web of Science ®Google Scholar
• Williams RS, Hillard JB, De Vane G, et al. A randomized, multicenter study comparing the efficacy of recombinant FSH vs recombinant FSH with Ganirelix during superovulation/IUI therapy. Am J Obstet Gynecol 2004;191:648–51
   PubMed Web of Science ®Google Scholar
• Gómez-Palomares JL, Juliá B, Acevedo-Martín B, et al. Timing ovulation for intrauterine insemination with a GnRH antagonist. Hum Reprod 2005;20:368–72
   PubMed Web of Science ®Google Scholar
• Allegra A, Marino A, Coffaro F, et al. GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial. Hum Reprod 2007;22:101–8
   PubMed Web of Science ®Google Scholar
• Crosignani PG, Somigliana E. Effect of GnRH antagonists in FSH mildly stimulated intrauterine insemination cycles: a multicentre randomized trial. Hum Reprod 2007;22:500–5
   PubMed Web of Science ®Google Scholar
• Gómez-Palomares JL, Acevedo-Martín B, Chávez M, et al. Multifollicular recruitment in combination with gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles. Fertil Steril 2008;89:620–4
   PubMed Web of Science ®Google Scholar
• Lambalk CB, Leader A, Olivennes F, et al. Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial. Hum Reprod 2006;21:632–9
   PubMed Web of Science ®Google Scholar
• Steward RG, Gill I, Williams DB, et al. Cetrorelix lowers premature luteinization rate in gonadotropin ovulation induction-intrauterine insemination cycles: a randomized-controlled clinical trial. Fertil Steril 2011;95:434–6
   PubMed Web of Science ®Google Scholar
• Cantineau AE, Cohlen BJ, Klip H, et al. The addition of GnRH antagonists in intrauterine insemination cycles with mild ovarian hyperstimulation does not increase live birth rates – a randomized, double-blinded, placebo-controlled trial. Hum Reprod 2011;26:1104–11
   PubMed Web of Science ®Google Scholar
• Bakas P, Konidaris S, Liapis A, et al. Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation. Fertil Steril 2011;95:2024–8
   PubMed Web of Science ®Google Scholar
• Kamath MS, Ramya R, Bhave P, et al. Effectiveness of GnRH antagonist in intrauterine insemination cycles. Eur J Obstet Gynecol Reprod Biol 2013;166:168–72
   PubMed Web of Science ®Google Scholar
• Graziano A, Caserta D, Piva I, et al. The addition of GnRH antagonists in intrauterine insemination cycles: a pilot study. Eur Rev Med Pharmacol Sci 2013;17:1604–10
   PubMed Web of Science ®Google Scholar
• Monraisin O, Chansel-Debordeaux L, Chiron A, et al. Evaluation of intrauterine insemination practices: a 1-year prospective study in seven French assisted reproduction technology centers. Fertil Steril 2016;105:1589–93
   PubMed Web of Science ®Google Scholar
• Tiboni GM, Palumbo P, Leonzio E, et al. Effectiveness of a low gonadotrophin-releasing hormone antagonist dose in preventing premature luteinizing hormone rise during controlled ovarian stimulation. Gynecol Endocrinol 2011;27:885–9
   PubMed Web of Science ®Google Scholar
• Kerimoğlu OS, Ercan CM, Keskin U, et al. Effect of a low dose of gonadotropin releasing hormone antagonist on in vitro fertilization outcomes. Arch Gynecol Obstet 2013;288:691–5
   PubMed Web of Science ®Google Scholar
• Lai Q, Hu J, Zeng D, et al. Assessing the optimal dose for Cetrorelix in Chinese women undergoing ovarian stimulation during the course of IVF-ET treatment. Am J Transl Res 2013;6:78–84
   PubMed Web of Science ®Google Scholar
• Gottardo F, Kliesch S. World Health Organization. Semen analysis: spermiogram according to WHO 2010 criteria. Urologe A 2010;50:101–8
   Google Scholar
• Kaplan PF, Katz SL, Thompson AK, Freund RD. Cycle fecundity in controlled ovarian hyperstimulation and intrauterine insemination. Influence of the number of mature follicles at hCG administration. J Reprod Med 2002;47:535–9
   PubMed Web of Science ®Google Scholar
• Houmard BS, Juang MP, Soules MR, Fujimoto VY. Factors influencing pregnancy rates with a combined clomiphene citrate/gonadotropin protocol for non-assisted reproductive technology fertility treatment. Fertil Steril 2002;77:384–6
   PubMed Web of Science ®Google Scholar
• A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone rises in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group. Hum Reprod 1998;13:3023–31
   PubMed Web of Science ®Google Scholar
• Chen HJ, Lin YH, Hsieh BC, et al. Is a lower dose of cetrorelix acetate effective for prevention of LH surge during controlled ovarian hyperstimulation? J Assist Reprod Genet 2006;23:289–92
   PubMed Web of Science ®Google Scholar
• Tzeng CR, Chen HJ, Lin YH, et al. Effect of a lower-dose cetrorelix acetate protocol on in-vitro fertilization outcome. Int J Gynaecol Obstet 2008;100:271–4
   PubMed Web of Science ®Google Scholar
• Messinis IE, Loutradis D, Domali E, et al. Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment. Hum Reprod 2005;20:3192–7
   PubMed Web of Science ®Google Scholar